newsfilter
← Latest News
Business Wire·

PepGen Announces Presentations at the 15th International Myotonic Dystrophy Consortium Highlighting Clinical Data from the PGN-EDODM1 Program

PEPG
  • PepGen Inc. (NASDAQ: PEPG) will present data from its PGN-EDODM1 program at the 15th International Myotonic Dystrophy Consortium (IDMC-15) in Saguenay, Quebec, Canada, from May 26-30, 2026.
  • CEO James McArthur, PhD, will deliver a late-breaking oral presentation on May 28, 2026, at 3:15–4:15pm EDT, focusing on individual patient mis-splicing data & natural history data for myotonic dystrophy type 1 (DM1).
  • Prior to the main conference, McArthur will present single & initial multiple ascending dose data for PGN-EDODM1 at the 6th Annual Pharma Day on May 26, 2026, at 11:00–11:20am EDT in Saguenay.
  • A poster session titled "The FREEDOM-DM1 clinical trial demonstrated strong splicing correction with single doses of PGN-EDODM1, with an acceptable safety profile" will be presented by Dr. Johanna Hamel of the University of Rochester Medical Center on May 27 & 28, 2026.
  • PGN-EDODM1 utilizes PepGen's proprietary EDO technology to restore normal MBNL1 splicing function by disrupting CUG repeat expansions in DMPK transcripts, allowing the transcripts to retain normal cellular function.
  • The U.S. FDA has granted PGN-EDODM1 both Orphan Drug & Fast Track Designations for DM1 treatment, while the European Medicines Agency (EMA) has granted it an Orphan Designation.
  • DM1 is a rare genetic neuromuscular disease affecting over 115,000 individuals in the U.S. & EU, characterized by multisystem symptoms & currently lacking approved disease-modifying therapies.
  • All presentations from IDMC-15 will be available on PepGen's website under Scientific Publications following the conference.